ArticleJournal of diabetes science and technology2026
A First Exploratory Study of Glycemic Outcomes During Normobaric Hypoxia Simulating Moderate-Altitude Conditions in Men With Type 1 Diabetes Using Automated Insulin Delivery, With Biochemical Comparison to Healthy Individuals.
Article in Journal of diabetes science and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhysical activity is essential in type 1 diabetes mellitus (T1DM) management, and hybrid closed-loop (HCL) insulin systems are now a preferred therapy. Data on the short-term metabolic effects of hypoxia remain limited.
methodsThis study evaluated the MiniMed 780G (MM780G) system in 12 men with T1DM (mean age 40.2 ± 3.9 years; diabetes duration 22.3 ± 8.7 years; glycated hemoglobin 6.4 ± 0.6%) before, during, and after 48 hours of simulated normobaric hypoxia, with a secondary aim of comparing selected biochemical markers with 13 age- and body mass index-matched healthy men. All participants underwent a 48-hour exposure to normobaric hypoxia in a normobaric chamber, simulating an altitude of up to 3500 m a.s.l. while maintaining normal barometric pressure. A broad panel of endocrine, immunological, vascular, neurotrophic, gastrointestinal, and oxidative biomarkers was assessed to characterize whole-body adaptation to hypoxia.
resultsAcross the three study periods, a numerical difference was observed only for SD, which was higher after the test compared with the hypoxia period itself in this exploratory analysis. No significant differences were found in other glycemic indices, daily carbohydrate intake, total insulin delivery, or the proportion of insulin administered as boluses (borderline significance); however, all changes remained within recommended glycemic thresholds. Insulin-like growth factor 1 (IGF-1) levels, at both baseline and delta, tended to be higher in the T1DM group, while changes in E-selectin were more pronounced than in controls.
conclusionsIn this exploratory study, 48-hour exposure to normobaric hypoxia simulating an altitude of 3500 m a.s.l. was not associated with statistically significant deterioration in glycemic control in men with well-controlled T1D treated with the MM780G system, with the exception of SD, suggesting that the recovery phase rather than the exposure period may represent the higher-risk window. However, this change did not translate into deviations from recommended glycemic ranges and warrants further investigation. Biomarker profiles revealed no significant differences in inflammation, stress response, or oxidative damage compared with healthy participants. Alterations in IGF-1 and E-selectin may indicate effective compensatory and adaptive mechanisms to moderate hypoxia in people with T1DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.